# Hyperpolarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy, Atezolizumab, and Bevacizumab

> **NCT06605664** · PHASE2 · RECRUITING · sponsor: **Chang Gung Memorial Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DIAGNOSTIC_TEST:** Hyperpolarized 13C pyruvate MRI

## Key facts

- **NCT ID:** NCT06605664
- **Lead sponsor:** Chang Gung Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2029-06-30
- **Final completion:** 2031-09-30
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06605664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06605664, "Hyperpolarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy, Atezolizumab, and Bevacizumab". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06605664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*